菜单
Suggests reducing bone turnover below the midpoint of the reference range for the chosen monitoring bone turnover marker to maximize the duration of remission. Triggered when aiming to sustain long-term remission after treatment and the marker exceeds the midpoint.
默认使用会先检查来源的 Prompt；你也可以切换为直接命令，或下载本地副本。
决定是否安装前，请先阅读 SKILL.md，以及 SkillsMP 当前展示的配套文件。
用 Codex 或 Claude 帮你安装 复制这段 Prompt，粘贴到 Codex、Claude 或其他助手里，让它检查 Skill 页面并帮你完成安装。
直接命令不会经过审查 Prompt；运行前请先检查来源。
npx skills add https://github.com/dromlakhani/MD2SKILL --skill endo-paget-remission-target-turnover命令会保持在同一行。复制前请横向滚动并检查完整内容。
想先保存到本地？可下载 SkillsMP 当前能够提供的文件。
正在显示 SKILL.md
基于 SOC 职业分类
| name | endo-paget-remission-target-turnover |
| description | Suggests reducing bone turnover below the midpoint of the reference range for the chosen monitoring bone turnover marker to maximize the duration of remission. Triggered when aiming to sustain long-term remission after treatment and the marker exceeds the midpoint. |
Collect a bone turnover marker (serum total ALP, P1NP, BSAP, CTx, or NTx) and its laboratory reference range; calculate the midpoint of the reference range.
If the post‑treatment marker value is above the midpoint, rule in the need for further suppression; if at or below the midpoint, rule out (target achieved).
Stratify the degree of excess above midpoint: mild (1‑25% above), moderate (26‑50% above), marked (>50% above) to guide intervention intensity.
For mild excess, optimize current regimen and repeat marker in 3‑6 months; for moderate or marked excess, consider a repeat potent bisphosphonate (e.g., second zoledronate infusion) or switch to a more potent agent, then re‑evaluate the marker.
Do not rely on symptoms alone; avoid over‑suppression that may cause adynamic bone; ensure adequate renal function before potent bisphosphonate; use least significant change to distinguish true change from assay variability; confirm marker specificity (e.g., bone‑specific ALP if liver disease); do not mistake transient fluctuations for true biological change.
A 68‑year‑old with polyostotic Paget’s disease received a single 5 mg IV zoledronate. Six months later serum ALP was 78 U/L (reference 30‑120 U/L, midpoint 75 U/L). Because the value was just above the midpoint, a second zoledronate infusion was given. At the following 6‑month visit ALP had fallen to 42 U/L (below midpoint), and the patient remained in biochemical remission at 5‑year follow‑up.
Source: Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2910